Skip to main content

Table 1 Patient characteristics

From: Effectiveness of medical supportive team for outpatients treated with sorafenib: a retrospective study

  Intervention group n = 31 (%) Non‐intervention group n = 39 (%) P-value
Age 70 67 0.578
Range 51-86 28-88  
Gender    1.000
Male 27(87.1) 35(89.7)  
Female 4(12.9) 4(10.3)  
ECOG PS    0.645
0 17(54.8) 17(43.6)  
1 12(38.7) 19(48.7)  
2 2(6.45) 3(7.7)  
Diagnosis    0.001*
HCC 31(100) 27(69.2)  
RCC - 12(30.8)  
Child-Pugh classification    0.233
A 29(93.5) 22(81.5)  
B 2(6.5) 5(18.5)  
Previous therapy    
HCC    0.186
None 7(22.6) 2(7.4)  
TACE 20(64.5) 22(81.5)  
HAIC 10(32.3) 3(11.1)  
RFA 10(32.3) 13(48.1)  
TAI 1(3.2) 1(3.7)  
Surgery 8(25.8) 3(11.1)  
Molecular-targeted therapy 2(6.5) -  
RCC    0.001*
None   3(25.0)  
RFA - 1(8.3)  
Interferon, Interleukin - 5(41.7)  
Surgery - 7(58.3)  
Molecular-targeted therapy - 4(33.3)  
Metastatic site    
HCC    0.672
Lung 9(29.0) 4(14.8)  
Lymph node 9(29.0) 3(11.1)  
Bone 3(9.7) 1(3.7)  
Other 4(12.9) 4(14.8)  
RCC    0.001*
Lung - 5(41.7)  
Lymph node - 4(33.3)  
Bone - 4(33.3)  
Liver - 3(25.0)  
Other - 6(50.0)  
  1. *P < 0.05.
  2. Abbreviations: ECOG PS: Eastern Cooperative Oncology Group performance status; HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; TACE: transarterial chemoembolization; HAIC: hepatic arterial infusion chemotherapy; RFA: radiofrequency ablation; TAI: transcatheter arterial infusion.